We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
Addition of investigational RNA-targeted medicines build upon Theratechnologiesโ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE...
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
New financing replaces existing credit facility to optimize Companyโs capital structureFavorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SVยฎ with simplified dosing for the treatment of excess abdominal fat in...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2ย million Fiscal 2024 guidance revised to...
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (โTheratechnologiesโ or the โCompanyโ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1 | 5.26315789474 | 1.9 | 2.28 | 1.87 | 95256 | 2.04018638 | CS |
4 | 0.23 | 12.9943502825 | 1.77 | 2.28 | 1.6 | 42267 | 1.91261345 | CS |
12 | 0.25 | 14.2857142857 | 1.75 | 2.28 | 1.59 | 45377 | 1.77416868 | CS |
26 | 0.32 | 19.0476190476 | 1.68 | 2.28 | 1.59 | 32300 | 1.8114272 | CS |
52 | -0.03 | -1.47783251232 | 2.03 | 3.43 | 1.59 | 31251 | 1.9943095 | CS |
156 | -14.96 | -88.2075471698 | 16.96 | 17.2 | 1.22 | 35844 | 4.62461404 | CS |
260 | -14.4 | -87.8048780488 | 16.4 | 22.4 | 1.22 | 66798 | 10.86454212 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions